MELAS综合征的磁共振波谱:与脑脊液和血浆代谢物水平的相关性及谷氨酰胺补充后的变化
本研究为观察性病例对照研究和开放标签单队列研究,纳入9例MELAS患者和9例性别年龄匹配对照,用单体素1H-MRS评估脑代谢,发现MELAS患者前额叶和顶枕叶皮质乳酸/肌酸比值升高,谷氨酸和谷氨酰胺(Glx/肌酸)无差异,补充谷氨酰胺后脑代谢物无显著变化,仅顶枕叶脑脊液乳酸与乳酸/肌酸比值呈正相关。
要点
- MELAS患者前额叶和顶枕叶皮质乳酸/肌酸比值较对照升高,波谱可显示乳酸峰。
- MELAS患者与对照的谷氨酸和谷氨酰胺(Glx/肌酸)在前额叶和顶枕叶均无显著差异。
- 口服谷氨酰胺补充后MELAS患者脑代谢物无显著变化,短周期MRS未能监测治疗反应。
核心结论
- MELAS患者补充谷氨酰胺后脑代谢物无显著变化;脑脊液乳酸与顶枕叶1H-MRS乳酸/肌酸比值呈正相关,但该工具无法监测短期治疗反应。
研究设计与样本
- 观察性病例对照研究及开放标签单队列研究,9例MELAS患者(35.8±3.2岁)和9例性别年龄匹配对照,单体素MRS(TE 144/35 ms),分析前额叶和顶枕叶皮质,jMRUI软件分析波谱。
关键影像表现/征象
- MELAS患者前额叶乳酸/肌酸为0.40±0.05,对照为0,p<0.001。
- MELAS患者顶枕叶乳酸/肌酸为0.32±0.03,对照为0,p<0.001。
- 前额叶Glx/肌酸组间比较p=0.930,顶枕叶p=0.310,均无显著差异。
诊断标准与关键数值
- MELAS患者前额叶乳酸/肌酸0.40±0.05 vs 对照0,p<0.001。
- MELAS患者顶枕叶乳酸/肌酸0.32±0.03 vs 对照0,p<0.001。
- 顶枕叶脑脊液乳酸与乳酸/肌酸比值正相关(0.85,p=0.003)。
临床应用与阅片要点
- 1H-MRS可显示MELAS患者前额叶和顶枕叶皮质乳酸/肌酸比值升高,提示乳酸峰。
- 谷氨酸和谷氨酰胺(Glx/肌酸)在MELAS与对照间无显著差异。
- 口服谷氨酰胺补充后短期MRS未见代谢物显著变化,作者认为该工具无法监测短期治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: MELAS syndrome is a genetic disorder caused by mitochondrial DNA mutations. We previously described that MELAS patients had increased CSF glutamate and decreased CSF glutamine levels and that oral glutamine supplementation restores these values. Proton magnetic resonance spectroscopy (1H-MRS) allows the in vivo evaluation of brain metabolism. We aimed to compare 1H-MRS of MELAS patients with controls, the 1H-MRS after glutamine supplementation in the MELAS group, and investigate the association between 1H-MRS and CSF lactate, glutamate, and glutamine levels.
METHODS: We conducted an observational case-control study and an open-label, single-cohort study with single-voxel MRS (TE 144/35 ms). We assessed the brain metabolism changes in the prefrontal (PFC) and parieto-occipital) cortex (POC) after oral glutamine supplementation in MELAS patients. MR spectra were analyzed with jMRUI software.
RESULTS: Nine patients with MELAS syndrome (35.8 ± 3.2 years) and nine sex- and age-matched controls were recruited. Lactate/creatine levels were increased in MELAS patients in both PFC and POC (0.40 ± 0.05 vs. 0, p < 0.001; 0.32 ± 0.03 vs. 0, p < 0.001, respectively). No differences were observed between groups in glutamate and glutamine (Glx/creatine), either in PFC (p = 0.930) or POC (p = 0.310). No differences were observed after glutamine supplementation. A positive correlation was found between CSF lactate and lactate/creatine only in POC (0.85, p = 0.003).
CONCLUSION: No significant metabolite changes were observed in the brains of MELAS patients after glutamine supplementation. While we found a positive correlation between lactate levels in CSF and 1H-MRS in MELAS patients, we could not monitor treatment response over short periods with this tool.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04948138; initial release 24/06/2021; first patient enrolled on 1/07/2021. https://clinicaltrials.gov/ct2/show/NCT04948138.
引用
- Guerrero-Molina MP, Bernabeu-Sanz Á, Ramos-González A, et al. Magnetic resonance spectroscopy in MELAS syndrome: correlation with CSF and plasma metabolite levels and change after glutamine supplementation. Neuroradiology. 2023. PMID: 38114794. doi:10.1007/s00234-023-03263-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。